December 16, 2021 -- Gretel announced a collaboration with Illumina to create synthetic genomic data that can be accessed by medical researchers globally. The companies also announced the release of a case study the partnership conducted that explores significant new use cases for synthetic data in genomics and related fields, including medical diagnosis, biotechnology, forensic biology, virology, and biological systematics.
The partnership will provide healthcare and life science practitioners access to highly statistically accurate, artificial versions of complex genomic datasets that align with the General Data Protection Regulation, the California Consumer Protection Act, and other major privacy laws. By using synthetic data, researchers can gain access to datasets immediately and avoid lengthy approval processes by institutional review boards, the firms said.
Additionally, this privacy-preserving method of sharing sensitive data allows for an accelerated and collaborative approach to next-generation DNA sequencing analysis, leading to the discovery of new drugs, insights into genetic disorders, and disease detection and treatments, the companies noted.